Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

Key Points Question Is there a role for platinum-based treatment in molecularly selected patients with advanced prostate cancer? Findings In a case series of 508 patients, platinum-based therapy was associated with antitumor activity, especially among patients with known DNA repair gene aberrations. In patients with DNA repair gene aberrations, nearly half had a decrease in prostate-specific antigen levels of at least 50% and experienced soft tissue responses. Meaning In patients with prostate cancer and DNA repair gene aberrations, platinum-based therapy may be considered a treatment option.

[1]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[2]  F. Feng,et al.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.

[3]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.

[4]  Chiun-Sheng Huang,et al.  Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer , 2020, Cancer science.

[5]  N. Tunariu,et al.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[6]  N. Agarwal,et al.  PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations , 2019, Annals of Oncology.

[7]  A. Bryce,et al.  Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses , 2019, Annals of Oncology.

[8]  N. Navin,et al.  Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. , 2019, The Lancet. Oncology.

[9]  BRcA Deficient Prostate Cancer Treated With Carboplatin or Docetaxel , 2019, Case Medical Research.

[10]  D. Olmos,et al.  BRCA2 and Other DDR Genes in Prostate Cancer , 2019, Cancers.

[11]  E. Gallardo,et al.  PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Chinnaiyan,et al.  Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency , 2019, European urology.

[13]  Paul Ellis,et al.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.

[14]  Thomas Wiegel,et al.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.

[15]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[16]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[17]  J. Mateo.  Point of Focus Debate : For Biomarkers for Metastatic Castration-resistant Prostate Cancer ( mCRPC ) : Yes or No ? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC , 2016 .

[18]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[20]  P. Nelson,et al.  Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[21]  M. Joerger,et al.  Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[23]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[25]  Observational Studies: Getting Clear about Transparency , 2014, PLoS medicine.

[26]  M. Rubin,et al.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.

[27]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[28]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[29]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[30]  William Berry,et al.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Escudier,et al.  Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  W. Oh,et al.  Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer? , 2007, Cancer.

[33]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[34]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[35]  H. Lynch,et al.  Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .